MULTIPLE MYELOMA

This study is comparing two different drug combinations for people newly diagnosed with multiple myeloma who are not eligible for stem cell transplant. About 160 participants will receive either elranatamab or daratumumab, both combined with three other standard myeloma drugs. Th…

This study aims to see if exercise and behavioral coaching can slow down accelerated aging in older adults who have survived blood cancers like leukemia and lymphoma. Researchers will enroll 180 participants aged 50+ and randomly assign them to different exercise programs to meas…

This early-stage study is testing whether adding an experimental drug called NT-I7 to standard CAR-T cell therapy helps control multiple myeloma for longer. The research will involve 40 adults with myeloma that has returned or stopped responding to other treatments. Participants …

This is the first study in people testing a new drug called SHR-3836 for multiple myeloma, a type of blood cancer. It aims to find a safe dose and see how the body handles the drug in 99 adults whose cancer has come back or stopped responding to standard treatments. The main goal…

This study is testing whether adding a fourth drug (isatuximab) to the standard three-drug combination works better for people with high-risk multiple myeloma who cannot receive stem cell transplants. Researchers will compare the four-drug combination against the standard three-d…

This study is testing whether a maintenance therapy for multiple myeloma can be given less often while still working well. It will give the drug combination daratumumab-hyaluronidase every 8 weeks instead of every 4 weeks, along with the pill lenalidomide, to patients who have ha…

This study is testing a new drug called CM336, a targeted antibody, as a maintenance therapy for people with newly diagnosed multiple myeloma who have had a stem cell transplant. The goal is to see if this drug can help eliminate any remaining traces of cancer cells and prevent t…

This study is for adults whose multiple myeloma, a type of blood cancer, has returned or stopped responding to prior treatments. The main goal is to see if giving the drug belantamab mafodotin less frequently, in combination with other standard cancer drugs, can still effectively…

This early-stage trial is testing a new, targeted radiation treatment for patients with high-risk multiple myeloma. The treatment involves an antibody that seeks out cancer cells and delivers a radioactive substance directly to them. This is given before a donor stem cell transpl…

This large trial aims to find the best dose for blood cancer drugs, testing if lower doses can control the disease just as well while causing fewer side effects. It will enroll 400 adults with conditions like multiple myeloma and Waldenstrom's macroglobulinemia. The study uses a …

This early-phase study is testing whether adding a personalized cancer vaccine can make a powerful cell therapy (CAR-T) work better for people with multiple myeloma that has come back or stopped responding to other treatments. The vaccine is made from a patient's own immune cells…

This study is testing an experimental drug called linvoseltamab for people with multiple myeloma whose cancer has returned after receiving a specific type of CAR-T cell therapy. The trial aims to see if this new treatment can help control the disease and is safe for these patient…

This study is testing whether personalized dosing guidelines for people with a specific blood type (Duffy null) can help them better tolerate standard cancer treatments. Researchers will enroll 90 people with multiple myeloma or triple-negative breast cancer to see if these tailo…

This study is testing a new type of personalized immune cell therapy called BCMA-GPRC5D CAR-T for people with advanced multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if this therapy is safe and can help patien…

This is a first-in-human study to test the safety and initial effects of a new drug called BL-M24D1. It is for adults with advanced multiple myeloma or other blood cancers that have come back or stopped responding to standard treatments. The main goals are to find a safe dose and…

This trial is testing if two already-approved cancer drugs, dabrafenib and trametinib, can help patients with rare cancers or common cancers that have a rare, specific genetic change called a BRAF V600 mutation. The drugs are already used for some cancers like melanoma, but resea…

This study is testing whether personalized treatment plans based on a patient's specific genetic risk factors can better control multiple myeloma, a blood cancer. Researchers will assign different treatment combinations to 200 newly diagnosed patients depending on whether they ha…

This is the first study in people to test a new drug called ABBV-438 for advanced multiple myeloma, a blood cancer that has returned or stopped responding to other treatments. The main goal is to find a safe dose and see how the body processes the drug. About 127 adults worldwide…

This is a first-in-human study to test the safety of a new, experimental CAR-T cell therapy called UF-KURE-BCMA for patients with multiple myeloma that has returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, modified in a lab to t…

This is a first-in-human study to test a new drug called IBI3003 for adults with multiple myeloma that has returned or stopped responding to at least three prior treatments. The first part aims to find a safe and tolerable dose. The second part will explore if the drug can help c…

This study aims to find the better initial treatment for adults newly diagnosed with multiple myeloma who are not candidates for a stem cell transplant. It will compare two different drug combinations: one featuring a targeted 'antibody-drug conjugate' (belantamab mafodotin) and …

This study is testing a new type of PET/CT scan that targets a specific protein (BCMA) found on multiple myeloma cancer cells. It aims to see if this scan can more accurately find and measure cancer spots throughout the body compared to current methods. The study will involve 300…

This study is testing whether adding a home-based breathing exercise program to standard physical therapy helps adults with multiple myeloma feel better. Researchers want to see if the combination reduces symptoms like fatigue, pain, and sleep problems. Participants will be rando…

This study aims to find out if taking fish oil supplements can help prevent or lessen nerve damage (peripheral neuropathy) caused by the chemotherapy drug bortezomib. It will involve 200 adults with multiple myeloma who are starting this specific chemo treatment. Researchers will…

This study is testing a phone app called FOCUS that teaches coping skills to help people with advanced cancer manage common symptoms like fatigue, anxiety, depression, and sleep problems. It aims to make this support more accessible to patients living in rural areas who may have …

This is an early-stage study to see how a new drug called QL2109 compares to an existing drug, Darzalex, in healthy men. Researchers will measure how the body processes each drug and check for safety and immune reactions. The goal is to see if QL2109 behaves similarly to the appr…

This study aims to find out if simple voice recordings from a smartphone can help detect a serious brain side effect called ICANS in patients receiving CAR T-cell therapy for lymphoma or multiple myeloma. Researchers will collect voice recordings and daily brain function assessme…